YM Biosciences: The Next Way To Get Long Myelofibrosis
Seeking Alpha
YM BiOSciences' Cheap Valuation Doesn't Make Sense
Seeking Alpha
Biotech 2012 Kickoff Party: Investor Preview
TheStreet.com
- Amag Pharmaceuticals
- Amarin
- Arena
- Ariad
- Biogen Idec
- Biomarin
- Celgene
- Clovis Oncology
- Dendreon
- Geron
- Gilead
- Human Genome Sciences
- Immunogen
- Incyte
- Indenix
- InterMune
- Keryx
- MannKind
- Medivation
- Merck KGaA
- Mesoblast
- ONYX Pharmaceuticals
- Regeneron
- Roche
- Seattle Genetics
- Spectrum Pharmaceuticals
- Vertex
- Vivus
- YM BioSciences
[video]4 Biotechs Dominating the Week
Motley Fool
Is YM the Next Incyte?
Minyanville
YM Bio's Myelofibrosis Drug Is For Real
TheStreet.com
December Catalysts for Drug and Biotech Stocks
Minyanville
6 Biotech Stocks Analysts Expect To Double In 2012
Seeking Alpha